• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Quantel’s Optimus Fusion receives FDA 501(k) clearance

Article

The U.S. Food and Drug Administration (FDA) has granted 501(k) clearance to Quantel Medical’s Optimus Fusion integrated laser platform.

Clermont-Ferrand, France-The U.S. Food and Drug Administration (FDA) has granted 501(k) clearance to Quantel Medical’s Optimus Fusion integrated laser platform.

According to the company, the Optimis Fusion system combines selective laser trabeculoplasty (SLT) photoregeneration therapy and traditional YAG photodisruption treatments to offer ophthalmologists an armamentarium for treating both cataract and glaucoma in a combination platform.

Effectively comanaging femtosecond laser-assisted cataract surgery

SLT therapy works by targeting melanin-rich cells that absorb the laser energy to induce a healing response, improving the function of the trabecular meshwork. Laser energy is delivered in short, fixed pulses over a large, homogeneous spot size, resulting in no thermal damage. SLT leaves structures intact, making it a repeatable procedure.

The YAG mode delivers photodisruption for capsulotomy and peripheral iridotomy surgical procedures. The gaussian laser beam profile allows for precise laser delivery at minimum energy levels, avoiding adverse side effects such as lens pitting. Precise tissue targeting is achieved with the advanced two-point aiming beam, allowing for fast and accurate targeting of the capsule, and an adjustable anterior and posterior offset feature allows for easy focus adjustment in front of, behind, or at the point of disruption.

Related Videos
World Optometry Day 2024
Nicholas Gilberg, OD, gives a tutorial on EssilorLuxottica's Leonardo team practice management programs
Chris and Jamie Shyer, Zyloware Eyewear co-CEOs, after their NOW Optical Lifetime Achievement award win at Vision Expo East
Jessica Steen, OD, FAAO, discusses systemic medication and ocular adverse effects at Vision Expo East 2024
At Vision Expo East 2024, Srinivas Kondapalli, MD, demonstrates how to use Rinsada to address ocular surface disease.
Brujic at Rinsada Booth at Vision Expo East 2024
© 2024 MJH Life Sciences

All rights reserved.